A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | DocumentType | Title | department | CollabParty | sponsor | Initial Submission | ExpirationDate | fy | fundSrc | branch | ||||||||||||||||
2 | CRADA-Cooperative Research & Development Agreement | COMBINED PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDIES EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE INDUCTION AND MAINTENANCE OF REMISSION IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (895) | DOM - GASTERENTOLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 1/13/2020 | 6/6/2022 | 2020 | Air Force | |||||||||||||||||
3 | COOP-Cooperative Agreement Letter | MAJOR EXTREMITY TRAUMA RESEARCH CONSORTIUM (METRC) – EARLY ADVANCED WEIGHT BEARING FOR PERI-ARTICULAR KNEE AND PILON INJURIES: AN RTC USING THE ANTI-GRAVITY TREADMILL (ALTERG) | DOO - ORTHOPAEDIC SERVICE | GENEVA | WRNMMC | 12/31/2019 | 2020 | USAMRAA | Air Force | |||||||||||||||||
4 | COOP-Cooperative Agreement Letter | MAJOR EXTREMITY TRAUMA RESEARCH CONSORTIUM (METRC) IMPROVING RECOVERY AFTER ORTHOPAEDIC TRAUMA: COGNITIVE-BEHAVIORAL BASED PHYSICAL THERAPY (CBPT) | DOO - ORTHOPAEDIC SERVICE | GENEVA | WRNMMC | 12/18/2019 | 2020 | USAMRAA | Air Force | |||||||||||||||||
5 | COOP-Cooperative Agreement Letter | A PROSPECTIVE STUDY OF EARLY MECHANICAL STABILIZATION AND BLEEDING IN DISRUPTION OF THE PELVIC RING | DOO - ORTHOPAEDIC SERVICE | GENEVA | 12/13/2019 | 2020 | USAMRAA | |||||||||||||||||||
6 | COOP-Cooperative Agreement Letter | DEVELOPMENT OF A SELF-REPORT INSTRUMENT FOR HIGH MOBILITY PROSTHESIS USERS: VALIDATION STUDY | DRM - CENTER FOR THE INTREPID | HJF | UNIVERSITY OF WASHINGTON | 12/13/2019 | 2020 | USAMRAA | Civilian | |||||||||||||||||
7 | CRADA-Cooperative Research & Development Agreement | STELLARIS: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS | DOM - GASTERENTOLOGY SERVICE | GENEVA | ALLERGAN PLC | 12/11/2019 | 4/8/2023 | 2020 | Army | |||||||||||||||||
8 | COOP-Cooperative Agreement Letter | NEEDS, PREFERENCES AND FUNCTIONAL ABILITIES OF VETERANS AND SERVICE MEMBERS WITH UPPER LIMB AMPUTATION | DRM - CENTER FOR THE INTREPID | HJF | 12/6/2019 | 2020 | USAMRAA | Civilian | ||||||||||||||||||
9 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY OF ORAL OZANIMOD FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 11/27/2019 | 2020 | Army | ||||||||||||||||||
10 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | DOM - GASTERENTOLOGY SERVICE | GENEVA | CELGENE CORP | 11/27/2019 | 2020 | Army | ||||||||||||||||||
11 | CRADA-Cooperative Research & Development Agreement | ROMAN: REDUCTION IN ORAL MUCOSITIS WITH AVASOPASEM MANGANESE (GC4419) – PHASE 3 TRIAL IN PATIENTS RECEIVING CHEMORADIOTHERAPY FOR LOCALLY-ADVANCED, NON-METASTATIC HEAD AND NECK CANCER | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | GALERA THERAPEUTICS, INC. | 11/18/2019 | 2020 | Air Force | ||||||||||||||||||
12 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CSL112 IN SUBJECTS WITH ACUTE CORONARY SYNDROME | DOM - CARDIOLOGY SERVICE | GENEVA | CSL BEHRING LLC | 11/4/2019 | 2020 | Army | ||||||||||||||||||
13 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTINATIONAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF MGL-3196 (RESMETIROM) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS AND/OR HEPATIC DECOMPENSATION | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | MADRIGAL PHARMACEUTICALS, INC | 10/31/2019 | 2020 | Army | ||||||||||||||||||
14 | COOP-Cooperative Agreement Letter | ULTRASOUND-GUIDED PERCUTANEOUS PERIPHERAL NERVE STIMULATION: A NON-PHARMACOLOGIC ALTERNATIVE FOR THE TREATMENT OF POSTOPERATIVE PAIN. | DOA - ANESTHESIA | HJF | UNIVERISTY OF CALIFORNIA | 10/4/2019 | 2020 | USAMRAA | Army | |||||||||||||||||
15 | CRADA-Cooperative Research & Development Agreement | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GENFIT | 10/4/2019 | 12/14/2021 | 2020 | Army | |||||||||||||||||
16 | CRADA-Cooperative Research & Development Agreement | ECO-RESET: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSE, MULTICENTER STUDY TO ASSESS EFFICACY AND SAFETY OF SER‑287 IN ADULTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | SERES THERAPEUTICS, INC. | 9/27/2019 | 2020 | Air Force | ||||||||||||||||||
17 | CRADA-Cooperative Research & Development Agreement | THE AIM-HN AND SEQ-HN STUDY: A 2 COHORT, NON-COMPARATIVE, PIVOTAL STUDY EVALUATING THE EFFICACY OF TIPIFARNIB IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) WITH HRAS MUTATIONS (AIM-HN) AND THE IMPACT OF HRAS MUTATIONS ON RESPONSE TO FIRST LINE SYSTEMIC THERAPIES FOR HNSCC (SEQ-HN) | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | KURA ONCOLOGY, INC. | 9/26/2019 | 2020 | Air Force | ||||||||||||||||||
18 | CRADA-Cooperative Research & Development Agreement | INDUCTION STUDY #2 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 9/26/2019 | 1/24/2024 | 2020 | Air Force | |||||||||||||||||
19 | CRADA-Cooperative Research & Development Agreement | SMART STEPPED CARE MANAGEMENT FOR LOW BACK PAIN IN MILITARY HEALTH SYSTEM | DRM - PHYSICAL THERAPY SERVICE | GENEVA | UNIVERSITY OF UTAH | 9/24/2019 | 2020 | Army | ||||||||||||||||||
20 | CRADA-Cooperative Research & Development Agreement | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE | DOM - CARDIOLOGY SERVICE | GENEVA | PFIZER | 9/18/2019 | 10/30/2019 | 2019 | Air Force | |||||||||||||||||
21 | COOP-Cooperative Agreement Letter | AUTOMATED CONTROL OF VOLUME MANAGEMENT SYSTEMS FOR PEOPLE WITH LIMB LOSS | DRM - CENTER FOR THE INTREPID | UNIVERSITY OF WASHINGTON | 9/11/2019 | 2019 | USAMRAA | Army | ||||||||||||||||||
22 | CRADA-Cooperative Research & Development Agreement | THE MOLECULAR PAP | DCI - DEPARTMENT OF CLINICAL INVESTIGATION | GYPSY BAY GENOMICS | 9/10/2019 | 2019 | Army | |||||||||||||||||||
23 | CRADA-Cooperative Research & Development Agreement | A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF ACALABRUTINIB (ACP-196) IN COMBINATION WITH VENETOCLAX WITH AND WITHOUT OBINUTUZUMAB COMPARED TO INVESTIGATOR’S CHOICE OF CHEMOIMMUNOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT DEL(17P) OR TP53 MUTATION | DOM - HEMOTOLOGY ONCOLOGY SERVICE | HJF | ACERTA PHARMA, LLC | 9/5/2019 | 2019 | Civilian | ||||||||||||||||||
24 | CRADA-Cooperative Research & Development Agreement | ECOSPOR III: A PHASE 3 MULTICENTER, RANDOMIZEED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SER-109 VS. PLACEBO TO REDUCE RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN ADULTS WHO HAVE RECEIVED ANTIBACTERIAL DRUG TREATMENT FOR RECURRENT CDI (RCDI). SHORT TITLE: "SERES-012." | DOM - GASTROENTEROLOGY SERVICE | GENEVA | SERES THERAPEUTICS, INC. | 8/16/2019 | 12/21/2022 | 2019 | Air Force | |||||||||||||||||
25 | CRADA-Cooperative Research & Development Agreement | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH HISTOLOGICALLY CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS (NASH) | DOM - GASTROENTEROLOGY SERVICE | GENEVA | NGM BIOPHARMACEUTICALS AUSTRALIA PTY LTD. | 8/9/2019 | 9/30/2021 | 2019 | Army | |||||||||||||||||
26 | CRADA-Cooperative Research & Development Agreement | STRATEGIC MANAGEMENT TO IMPROVE CRT USING MULTI-SITE PACING POST APPROVAL STUDY | DOM - CARDIOLOGY SERVICE | GENEVA | BOSTON SCIENTIFIC CRM | 7/30/2019 | 2019 | Army | ||||||||||||||||||
27 | CRADA-Cooperative Research & Development Agreement | A PROSTHETIC FOOT EMULATOR TO OPTIMIZE PRESCRIPTION OF PROSTHETIC FEET IN VETERANS AND SERVICE MEMBERS WITH LEG AMPUTATIONS | DRM - CENTER FOR THE INTREPID | HJF | US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY | 7/18/2019 | 8/31/2019 | 2019 | Army | |||||||||||||||||
28 | CRADA-Cooperative Research & Development Agreement | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | TAKEDA GLOBAL RESEARCH | 7/16/2019 | 6/26/2021 | 2019 | ||||||||||||||||||
29 | CRADA-Cooperative Research & Development Agreement | DECREASING SUICIDE RISK AMONG SERVICE MEMBERS WITH POSTTRAUMATIC STRESS USING WRITTEN EXPOSURE THERAPY | DBH - BEHAVIORAL HEALTH SERVICE | UTHSCSA | 7/15/2019 | 2020 | MRMC | Army | ||||||||||||||||||
30 | CRADA-Cooperative Research & Development Agreement | TARGETING CHRONIC PAIN IN PRIMARY CARE SETTINGS USING INTERNAL BEHAVIORAL HEALTH CONSULTANTS | DBH - BEHAVIORAL HEALTH SERVICE | UTHSCSA | 7/15/2019 | 2020 | MRMC | Civilian | ||||||||||||||||||
31 | CRADA-Cooperative Research & Development Agreement | TREATMENT PATTERNS, OUTCOMES, AND PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE: A PROSPECTIVE DISEASE REGISTRY OF PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH NOVEL AGENTS | DOM - HEMOTOLOGY ONCOLOGY SERVICE | HJF | ASTRAZENECA PHARMACEUTICALS | 7/2/2019 | 2019 | Civilian | ||||||||||||||||||
32 | COOP-Cooperative Agreement Letter | MORE RESILIENCY RELIABILITY AND VALIDITY | DRM - BRAIN INJURY REHABILITATION SERVICE | HJF | 6/28/2019 | 7/7/2024 | 2019 | USAMRAA | Civilian | |||||||||||||||||
33 | COOP-Cooperative Agreement Letter | LUNG ULTRASOUND WITH NEURAL-NET GENERATED POINT-OF-CARE IDENTIFICATION OF INJURY TRIAL (LUNG-POINT) | DOM - PULMONARY | GENEVA | UNIFORMED SERVICES UNIVERSITY OF HEALTH SCIENCES | 6/24/2019 | 7/29/2024 | 2019 | DARPA | Civilian | ||||||||||||||||
34 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, RANDOMIZED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF UBLITUXIMAB IN COMBINATION WITH IBRUTINIB COMPARED TO IBRUTINIB ALONE, IN PATIENTS WITH PREVIOUSLY TREATED HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | TG THERAPEUTICS, INC. | 5/21/2019 | 9/21/2020 | 2019 | Air Force | |||||||||||||||||
35 | CRADA-Cooperative Research & Development Agreement | A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC) | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | BOSTON BIOMEDICAL, INC. | 5/13/2019 | 11/2/2022 | 2019 | Air Force | |||||||||||||||||
36 | CRADA-Cooperative Research & Development Agreement | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH HISTOLOGICALLY CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS (NASH) | DOM - GASTROENTEROLOGY SERVICE | GENEVA | NGM BIOPHARMACEUTICALS AUSTRALIA PTY LTD. | 5/1/2019 | 9/30/2020 | 2019 | Army | |||||||||||||||||
37 | CRADA-Cooperative Research & Development Agreement | APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION | DOM - CARDIOLOGY SERVICE | GENEVA | HAMILTON HEALTH SCIENCES | 4/23/2019 | 12/13/2022 | 2019 | Army | |||||||||||||||||
38 | CRADA-Cooperative Research & Development Agreement | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE | DOM - CARDIOLOGY SERVICE | GENEVA | PFIZER | 4/23/2019 | 10/30/2019 | 2019 | Army | |||||||||||||||||
39 | CRADA-Cooperative Research & Development Agreement | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FILGOTINIB IN SUBJECTS WITH CROHN’S DISEASE." SHORT TITLE: "GS-US-419-3896." | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 4/5/2019 | 1/21/2023 | 2019 | Air Force | |||||||||||||||||
40 | CRADA-Cooperative Research & Development Agreement | A LONG TERM-EXTENSION STUDY TO EVALUATE THE SAFETY OF FILGOTINIB IN SUBJECTS WITH ULCERATIVE COLITIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 4/5/2019 | 4/8/2023 | 2019 | Air Force | |||||||||||||||||
41 | COOP-Cooperative Agreement Letter | ASSESSING REHABILITATION OUTCOMES AFTER SEVERE NEUROMUSCULOSKELETAL INJURY: DEVELOPMENT OF PATIENT REPORTED OUTCOMES ASSESSMENT INSTRUMENTS | DOO - ORTHOPAEDIC SERVICE (CFI) | HJF | UNIVERSITY OF Delaware | 4/3/2019 | 2019 | USAMRAA | Civilian | |||||||||||||||||
42 | Data-Use Agreement | DATA SHARING AGREEMENT BETWEEN THE JOINT PATHOLOGY CENTER (JPC)AND BROOKE ARMY MEDICAL CENTER (BAMC) FOR ACTUR DATA SHARING AGREEMENT FOR RESEARCH PROTOCOL | DOS - OTOLARYNGOLOGY SERVICE | JOINT PATHOLOGY CENTER | 3/13/2019 | 3/31/2024 | 2019 | Air Force | ||||||||||||||||||
43 | CRADA-Cooperative Research & Development Agreement | MORE TECH - AUTOMATED ASSESSMENT OF A REHABILITATION OUTCOMES | DOO - ORTHOPAEDIC SERVICE (CFI) | OTTO BOCK HEALTHCARE GMBH | 3/6/2019 | 10/25/2023 | 2019 | Civilian | ||||||||||||||||||
44 | CRADA-Cooperative Research & Development Agreement | A PHASE 2B RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION OF UBLITUXIMAB + TGR-1202 WITH OR WITHOUT BENDAMUSTINE AND TGR-1202 ALONE IN PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN’S LYMPHOMA." SHORT TITLE: "UTX-TGR-205 | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | TG THERAPEUTICS, INC. | 2/22/2019 | 12/21/2022 | 2019 | Air Force | |||||||||||||||||
45 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, LONG-TERM, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF OBETICHOLIC ACID IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. | DOM - GASTROENTEROLOGY SERVICE | GENEVA | INTERCEPT PHARMACEUTICALS, INC | 2/20/2019 | 7/18/2021 | 2019 | Army | |||||||||||||||||
46 | CRADA-Cooperative Research & Development Agreement | BLOOD SAMPLE COLLECTION TO EVALUATE BIOMARKERS IN SUBJECTS WITH UNTREATED SOLID TUMORS | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | EXACT SCIENCES CORPORATION | 2/13/2019 | 2/21/2024 | 2019 | Air Force | |||||||||||||||||
47 | CRADA-Cooperative Research & Development Agreement | A SINGLE COHORT PHASE 4 TRIAL INVESTIGATING THE IMPACT OF G-CSF PRIMARY PROPHYLAXIS FOR ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS TREATED WITH A+AVD | DOM - HEMOTOLOGY ONCOLOGY SERVICE | HJF | SEATTLE GENETICS | 2/8/2019 | 2/26/2024 | 2019 | Army | |||||||||||||||||
48 | CRADA-Cooperative Research & Development Agreement | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE-CONTROLLED 8-WEEK STUDY TO EVALUATE THE EFFECT OF SACUBITRIL AND VALSARTAN (LCZ696) VERSUS ENALAPRIL ON CHANGES IN NT-PROBNP AND SAFETY AND TOLERABILITY OF IN-HOSPITAL INITIATION OF LCZ696 COMPARED TO ENALAPRIL IN HFREF PATIENTS WHO HAVE BEEN STABILIZED FOLLOWING HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE (ADHF). | DOM - CARDIOLOGY SERVICE | GENEVA | NOVARTIS PHARMACEUTICALS | 2/1/2019 | 6/7/2022 | 2019 | Army | |||||||||||||||||
49 | CRADA-Cooperative Research & Development Agreement | AN OPEN-LABEL, 2 X 2 FACTORIAL, RANDOMIZED CONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY OF APIXABAN VS. VITAMIN K ANTAGONIST AND ASPIRIN VS. ASPIRIN PLACEBO IN SUBJECTS WITH ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME OR PERCUTANEOUS CORONARY INTERVENTION | DOM - CARDIOLOGY SERVICE | GENEVA | BRISTOL-MYERS SQUIBB COMPANY | 1/30/2019 | 1/31/2021 | 2019 | Army | |||||||||||||||||
50 | CRADA-Cooperative Research & Development Agreement | A PHASE 2B, PROSPECTIVE, DOUBLE-BLINDED, RANDOMIZED CONTROLLED TRAIL OF THE MICRONIZED DHACM INJECTION AS COMPARED TO SALINE PLACEBO INJECTION THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE | DOO - ORTHOPAEDIC SERVICE | GENEVA | MIMEDX GROUP INC. | 1/28/2019 | 2/13/2024 | 2019 | Army | |||||||||||||||||
51 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION TRIAL OF ORAL RPC1063 AS THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 1/25/2019 | 1/21/2023 | 2019 | Air Force | |||||||||||||||||
52 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL RPC1063 AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS.” SHORT TITLE: “RPC01-3101" | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 1/25/2019 | 12/14/2022 | 2019 | Air Force | |||||||||||||||||
53 | CRADA-Cooperative Research & Development Agreement | A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE TREATMENT OF PERIANAL FISTULIZING CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 1/16/2019 | 12/14/2022 | 2019 | Air Force | |||||||||||||||||
54 | COOP-Cooperative Agreement Letter | VALIDATION OF THE START BACK SCREENING TOOL IN PRIMARY CARE MANAGEMENT OF BACK PAIN IN THE MILITARY HEALTH SYSTEM: A RANDOMIZED TRIAL OF RISK-STRATIFIED CARE | DOO - ORTHOPAEDIC SERVICE (CFI) | GENEVA | USAMRMC | 12/28/2018 | 2019 | MRMC | Army | |||||||||||||||||
55 | MTA-Material Transfer Agreement | A PROSPECTIVE DATABASE REGISTRY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | DOM - GASTROENTEROLOGY SERVICE | SEATTLE VA MED CENTER | 12/6/2018 | 2/25/2024 | 2019 | Army | ||||||||||||||||||
56 | CRADA-Cooperative Research & Development Agreement | IDENTIFICATION OF FACTORS THAT INFLUENCE RETURN TO DUTY | DRM - CENTER FOR THE INTREPID | SENTIER STRATEGIC RESOURCES, LLC | 12/4/2018 | 1/9/2021 | 2019 | Civilian | ||||||||||||||||||
57 | COOP-Cooperative Agreement Letter | EXPLORING THE VALUE OF THE DOD/VA CLINICAL PRACTICE GUIDELINES FOR NON-SURGICAL MANAGEMENT OF KNEE OSTEOARTHRITIS IN THE MILITARY HEALTH SYSTEM | DOO - ORTHOPAEDIC SERVICE (CFI) | GENEVA | CDMRP | 11/13/2018 | 2019 | USAMRAA | Army | |||||||||||||||||
58 | CRADA-Cooperative Research & Development Agreement | CORE-SCORE PHASE 1: IMPLEMENTATION OF A BRIEF COGNITIVE REHABILITATION INTERVENTION TO ENHANCE EFFICIENCY OF SERVICE DELIVERY FOR SERVICE MEMBERS AND VETERANS WITH MTBI | DRM - BRAIN INJURY REHABILITATION SERVICE | HJF | CDMRP | 11/13/2018 | 2/20/2024 | 2019 | CDMRP | Civilian | ||||||||||||||||
59 | CRADA-Cooperative Research & Development Agreement | INDUCTION STUDY #2 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 10/25/2018 | 1/24/2024 | 2019 | Air Force | |||||||||||||||||
60 | CRADA-Cooperative Research & Development Agreement | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EMRICASAN, AN ORAL CASPASE INHIBITOR, IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS AND SEVERE PORTAL HYPERTENSION | DOM - GASTERENTOLOGY SERVICE | GENEVA | CONATUS PHARMACEUTICALS | 10/16/2018 | 12/21/2021 | 2019 | Army | |||||||||||||||||
61 | CRADA-Cooperative Research & Development Agreement | A RANDOMIZED, CONTROLLED, OPEN-LABEL, GLOBAL PHASE 3 STUDY COMPARING THE EFFICACY OF THE ANTI-PD-1 ANTIBODY BGB-A317 VERSUS CHEMOTHERAPY AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED UNRESECTABLE/METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA." SHORT TITLE: "BGB-A317-302 | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | HEALTH RESEARCHTX LLC | 10/15/2018 | 2019 | Army | ||||||||||||||||||
62 | CRADA-Cooperative Research & Development Agreement | EVALUATING THE DIAGNOSTIC PERFORMANCE OF NEAR INFRARED SPECTROSCOPY (NIRS) IN THE SETTING OF ACUTE COMPARTMENT SYNDROME (ACS) IN TRAUMATIZED LOWER EXTREMITIE | DOO - ORTHOPAEDIC SERVICE | GENEVA | NONIN, INC. | 10/9/2018 | 1/22/2024 | 2019 | Air Force | |||||||||||||||||
63 | CRADA-Cooperative Research & Development Agreement | MICROCURRENT THERAPY FOR CHRONIC LOW BACK PAIN: A RANDOMIZED CONTROLLED TRIAL | DCIS - NURSING OPERATIONS - CNSCI | GENEVA | UNIFORMED SERVICES UNIVERSITY OF HEALTH SCIENCES | 9/25/2018 | 10/22/2023 | 2019 | TRI-NURSING | Army | ||||||||||||||||
64 | CRADA-Cooperative Research & Development Agreement | A RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENZASTAURIN PLUS R-CHOP VERSUS R-CHOP IN TREATMENT-NAÏVE SUBJECTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA WHO POSSESS THE NOVEL GENOMIC BIOMARKER DGM1 (“CLINICAL STUDY”) | DOM - HEMOTOLOGY ONCOLOGY SERVICE | HJF | DENOVO BIOPHARMA, LLC | 9/13/2018 | 9/28/2023 | 2018 | ||||||||||||||||||
65 | MTA-Material Transfer Agreement | ULTRASOUND DETECTION OF PNEUMOTHORAX BY MILITARY MEDICS PREVIOUSLY NAÏVE TO SONOGRAPHY. A SINGLE-BLINDED CROSS-SECTIONAL STUDY DESIGN USING CADAVER MODELS | DEM - EMERGENCY MEDICINE | FUJIFILM SONOSITE | 9/7/2018 | 9/21/2023 | 2018 | |||||||||||||||||||
66 | CRADA-Cooperative Research & Development Agreement | TELEHEALTH 2.0: PRESERVING CONTINUITY OF BEHAVIORAL HEALTH CLINICAL CARE TO PATIENTS USING MOBILE DEVICES | DBH - BEHAVIORAL HEALTH SERVICE | UTHSCSA | CDMRP | 8/13/2018 | 9/29/2020 | 2019 | CDMRP | USPHS | ||||||||||||||||
67 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL RPC1063 AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS.” SHORT TITLE: “RPC01-3101" | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 8/13/2018 | 12/14/2022 | 2018 | ||||||||||||||||||
68 | CRADA-Cooperative Research & Development Agreement | PATTERNS OF HEALTHCARE UTILIZATION AFTER MUSCULOSKELETAL INJURIES OF THE SPINE AND UPPER EXTREMITY IN THE MHS | DRM - PHYSICAL THERAPY SERVICE | DUKE UNIVERSITY | CDMRP | 8/10/2018 | 11/5/2022 | 2019 | CDMRP | Army | ||||||||||||||||
69 | CRADA-Cooperative Research & Development Agreement | Healthcare Utilization Patterns in Patients with Lower Extremity Injuries | DRM - PHYSICAL THERAPY SERVICE | DUKE UNIVERSITY | CDMRP | 8/10/2018 | 11/5/2022 | 2019 | CDMRP | Army | ||||||||||||||||
70 | CRADA-Cooperative Research & Development Agreement | A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC) | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | BOSTON BIOMEDICAL, INC. | 8/10/2018 | 11/2/2022 | 2018 | Air Force | |||||||||||||||||
71 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBETICHOLIC ACID IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | INTERCEPT PHARMACEUTICALS, INC | 8/6/2018 | 8/14/2023 | 2018 | ||||||||||||||||||
72 | CRADA-Cooperative Research & Development Agreement | TRAUMA OUTCOMES AND UROGENITAL HEALTH IN OEF/OIF (TOUGH) – A RETROSPECTIVE COHORT STUDY WITH LONG-TERM FOLLOW-UP | DOS - UROLOGY SERVICE | UTHSCSA | 7/23/2018 | 8/24/2023 | 2018 | |||||||||||||||||||
73 | CRADA-Cooperative Research & Development Agreement | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION | DOM - CARDIOLOGY SERVICE | GENEVA | AMGEN, INC. | 7/17/2018 | 4/8/2023 | 2018 | ||||||||||||||||||
74 | CRADA-Cooperative Research & Development Agreement | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO VALSARTAN, ON MORBIDITY AND MORTALITY IN HEART FAILURE PATIENTS (NYHA CLASS II-IV) WITH PRESERVED EJECTION FRACTION | DOM - CARDIOLOGY SERVICE | GENEVA | NOVARTIS PHARMACEUTICALS CORP. | 7/11/2018 | 2/8/2020 | 2018 | ||||||||||||||||||
75 | CRADA-Cooperative Research & Development Agreement | A PROSPECTIVE NON-INVASIVE STUDY OF CEREBRAL BLOOD FLOW VELOCITY MORPHOLOGY FOR QUANTIFICATION OF INTRACRANIAL PRESSURE | DOS - SURGICAL CRITICAL CARE SERVICE | HJF | NEURAL ANALYTICS INC | 6/21/2018 | 7/31/2022 | 2018 | ||||||||||||||||||
76 | CRADA-Cooperative Research & Development Agreement | STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON THE INCIDENCE OF WORSENING HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION | DOM - CARDIOLOGY SERVICE | GENEVA | ASTRAZENECA PHARMACEUTICALS | 5/31/2018 | 8/15/2022 | 2018 | ||||||||||||||||||
77 | CRADA-Cooperative Research & Development Agreement | ESTABLISHMENT OF A TISSUE REPOSITORY FOR THE MURTHA CANCER CENTER BIOBANK (MCCB) AT BAMC | DPALS - PATHOLOGY SERVICE | HJF | UNIFORMED SERVICES UNIVERSITY OF HEALTH SCIENCES | 5/16/2018 | 6/30/2023 | 2018 | ||||||||||||||||||
78 | CRADA-Cooperative Research & Development Agreement | PATTERN OF USE AND SAFETY/EFFECTIVENESS OF NIVOLUMAB IN ROUTINE ONCOLOGY PRACTICE | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | BRISTOL-MYERS SQUIBB COMPANY | 4/23/2018 | 7/13/2022 | 2018 | ||||||||||||||||||
79 | CRADA-Cooperative Research & Development Agreement | A PATIENT TOOLKIT FOR THE TRANSITION OF CARE OF ACTIVE DUTY PATIENTS WITH IBD TO THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM | DOM - GASTERENTOLOGY SERVICE | GENEVA | AMERICAN COLLEGE OF GASTROENTEROLOGY | 4/16/2018 | 7/21/2023 | 2018 | ||||||||||||||||||
80 | CRADA-Cooperative Research & Development Agreement | A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE TREATMENT OF PERIANAL FISTULIZING CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 4/13/2018 | 12/14/2022 | 2018 | ||||||||||||||||||
81 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION TRIAL OF ORAL RPC1063 AS THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 4/5/2018 | 1/21/2023 | 2018 | ||||||||||||||||||
82 | CRADA-Cooperative Research & Development Agreement | ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI). SHORT TITLE: "SERES-013." | DOM - GASTROENTEROLOGY SERVICE | GENEVA | SERES THERAPEUTICS, INC. | 4/5/2018 | 12/21/2022 | 2018 | ||||||||||||||||||
83 | CRADA-Cooperative Research & Development Agreement | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION | DOM - CARDIOLOGY SERVICE | GENEVA | AMGEN, INC. | 3/19/2018 | 4/8/2023 | 2018 | ||||||||||||||||||
84 | CRADA-Cooperative Research & Development Agreement | MORE TECH - AUTOMATED ASSESSMENT OF A REHABILITATION OUTCOMES | DOO - ORTHOPAEDIC SERVICE (CFI) | OTTO BOCK HEALTHCARE GMBH | 3/16/2018 | 10/25/2023 | 2019 | Civilian | ||||||||||||||||||
85 | CRADA-Cooperative Research & Development Agreement | AMENDMENT 1 TO MASTER CRADA | DCI - DEPARTMENT OF CLINICAL INVESTIGATION | METIS | 3/12/2018 | 2018 | ||||||||||||||||||||
86 | CRADA-Cooperative Research & Development Agreement | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL RPC1063 AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS.” SHORT TITLE: “RPC01-3101" | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CELGENE CORP | 3/8/2018 | 12/14/2022 | 2018 | ||||||||||||||||||
87 | CRADA-Cooperative Research & Development Agreement | “A MULTINATIONAL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF TESETAXEL PLUS A REDUCED DOSE OF CAPECITABINE VERSUS CAPECITABINE ALONE IN PATIENTS WITH HER2 NEGATIVE, HORMONE RECEPTOR POSITIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH A TAXANE”. SHORT TITLE, “ODENATE 2018.023” | DOM - HEMOTOLOGY ONCOLOGY SERVICE | HJF | ODONATE THERAPEUTICS LLC | 3/7/2018 | 3/31/2023 | 2018 | ||||||||||||||||||
88 | CRADA-Cooperative Research & Development Agreement | STELLARIS: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS | DOM - GASTERENTOLOGY SERVICE | GENEVA | ALLERGAN PLC | 2/26/2018 | 4/9/2023 | 2018 | ||||||||||||||||||
89 | CRADA-Cooperative Research & Development Agreement | EFFICACY STUDY OF INECALCITOL IN COMBINATION WITH DECITABINE IN ACUTE MYELOID LEUKEMIA PATIENTS UNFIT FOR STANDARD CHEMOTHERAPY | DOM - HEMOTOLOGY ONCOLOGY SERVICE | HJF | HYBRIGENICS | 2/26/2018 | 3/31/2023 | 2018 | ||||||||||||||||||
90 | CRADA-Cooperative Research & Development Agreement | COMBINED PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDIES EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE INDUCTION AND MAINTENANCE OF REMISSION IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 2/20/2018 | 4/8/2023 | 2018 | ||||||||||||||||||
91 | MTA-Material Transfer Agreement | LUNG ULTRASOUND WITH NEURAL-NET GENERATED POINT-OF-CARE IDENTIFICATION OF INJURY TRIAL (LUNG-POINT) | DOM - PULMONARY | INVENTIVE GOVERNMENT SOLUTIONS, LLC | 2/20/2018 | 2018 | ||||||||||||||||||||
92 | CRADA-Cooperative Research & Development Agreement | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN’S DISEASE | DOM - GASTROENTEROLOGY SERVICE | GENEVA | TAKEDA GLOBAL RESEARCH | 2/14/2018 | 6/26/2021 | 2018 | ||||||||||||||||||
93 | CRADA-Cooperative Research & Development Agreement | A PHASE 3 STUDY COMPARING DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN SUBJECTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR HIGH DOSE THERAPY | DOM - HEMOTOLOGY ONCOLOGY SERVICE | GENEVA | JANSSEN RESEARCH & DEVELOPMENT LLC | 2/14/2018 | 12/20/2025 | 2018 | ||||||||||||||||||
94 | MTA-Material Transfer Agreement | A PROSPECTIVE DATABASE REGISTRY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | DOM - GASTROENTEROLOGY SERVICE | WESTMEAD INSTITUTE FOR MEDICAL RESEARCH | 2/5/2018 | 2018 | ||||||||||||||||||||
95 | MTA-Material Transfer Agreement | MULTI-INSTITUTIONAL, PROSPECTIVE STUDY OF DIRECT SINGLE-STAGE IMPLANTATION OF SACRAL NEUROMODULATION | DOS - UROLOGY SERVICE | LOMA LINDA UNIVERSITY MED CTR | 1/30/2018 | 4/8/2020 | 2018 | |||||||||||||||||||
96 | CRADA-Cooperative Research & Development Agreement | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH HISTOLOGICALLY CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS (NASH) | DOM - GASTROENTEROLOGY SERVICE | GENEVA | NGM BIOPHARMACEUTICALS AUSTRALIA PTY LTD. | 1/3/2018 | 9/30/2020 | 2018 | ||||||||||||||||||
97 | MTA-Material Transfer Agreement | American College of Radiology NORMATIVE NEUROIMAGING LIBRARY | DOR - RADIOLOGY SERVICE | HEALTH RESEARCHTX LLC | 12/27/2017 | 2/20/2023 | 2018 | |||||||||||||||||||
98 | CRADA-Cooperative Research & Development Agreement | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FILGOTINIB IN SUBJECTS WITH CROHN’S DISEASE." SHORT TITLE: "GS-US-419-3896." | DOM - GASTROENTEROLOGY SERVICE | GENEVA | GILEAD SCIENCES, INC. | 12/18/2017 | 1/21/2023 | 2018 | ||||||||||||||||||
99 | CRADA-Cooperative Research & Development Agreement | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EMRICASAN, AN ORAL CASPASE INHIBITOR, IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS AND SEVERE PORTAL HYPERTENSION SHORT TITLE: "IDN-6556-14" | DOM - GASTROENTEROLOGY SERVICE | GENEVA | CONATUS PHARMACEUTICALS | 12/14/2017 | 12/21/2022 | 2018 | ||||||||||||||||||
100 | CRADA-Cooperative Research & Development Agreement | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF EMRICASAN, AN ORAL CASPASE INHIBITOR, IN SUBJECTS WITH DECOMPENSATED NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS" SHORT TITLE: "IDN-6556-17" | DOM - GASTERENTOLOGY SERVICE | GENEVA | CONATUS PHARMACEUTICALS | 12/8/2017 | 12/21/2022 | 2018 |